Co-administration with the GLA-AF immunostimulant augmented the humoral immune response to the Na-APR-1 antigen, although the level of antibodies that will be required for protection remains to be established in larger Phase 2 and 3 clinical field trials or controlled human hookworm infection (CHHI) studies. Here, MAGEH1 is linked to ancylostomiasis.